Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Barbara Herkert,Audrey Kauffmann, Sandra Mollé,Christian Schnell, Thomas Ferrat,Hans Voshol, Janina Juengert, Hélène Erasimus, Grégory Marszalek, Malika Kazic-Legueux,Eric Billy,David Ruddy,Mark Stump,Daniel Guthy, Mitko Ristov,Keith Calkins,Sauveur-Michel Maira,William R. Sellers,Francesco Hofmann,Michael N. Hall,Saskia M. Brachmann

crossref（2023）

引用 0|浏览0

暂无评分

摘要

PI3Kβi (rac-KIN-193) treatment induces the interaction of p85 with a panel of proteins in PTEN^LOF/BRAF^MUT melanoma. RVH-421 were treated with DMSO or 1μM PI3Kβi for 2h. Lysates were subjected to immunoprecipitation using an antibody targeting p85. Proteins in the range of 75 to 250 kDa were identified by LC-MS as described. Total spectra counts were used as a measure for protein quantity. The table summarizes the proteins enriched upon PI3Kβi treatment in the p85 precipitate. A spectral count ratio of 4 (log₂ (PI3Kβi /DMSO) > 2) was taken as an arbitrary cutoff for significant enrichment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in &lt;i&gt;PTEN&lt;/i&gt;&lt;sup&gt;LOF&lt;/sup&gt;&lt;i&gt;/BRAF&lt;/i&gt;&lt;sup&gt;MUT&lt;/sup&gt; Melanoma through PI3K and IGF1R Inhibition

Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition